Teva buys 51% stake in Genomic-Analysis Company Immuneering for $60 million

The acquisition gives Teva exclusive rights to Immuneering's cutting-edge analytics to advance treatments for diseases of the CNS.

Teva CEO Erez Vigodman

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has announced the acquisition of 51% of Immuneering Corporation, a privately-held genomic-analysis company based in Cambrige, Massachusetts. Immuneering uses advanced proprietary techniques to identify hidden signals and biological insights across an array of genetic, genomic, and proteomic data that can direct research for enhanced discovery, development and clinical success.

Teva and Immuneering have worked together over the past several years to unlock significant findings into genetic biomarkers, therapy-specific gene expression signatures and breakthrough work in characterizing non-biological complex drugs (NBCDs). Teva’s majority holding in Immuneering will provide right of first refusal in projects relating to the company’s stated objective of developing, personalizing and improving treatment of disorders of the Central Nervous System (CNS).

“Immuneering brings together state-of-the-art analytics know-how with expertise in integrating multiple biologically- and clinically-relevant inputs, ” said Michael Hayden, President, Teva Global R&D, and Chief Scientific Officer. “Their ability to cut through, link and interpret enormous and disparate data-sets is outstanding. This capability is invaluable in capturing difficult-to-find signals, confirming them in follow-up experiments, and informing decision-making that de-risks and optimizes development of therapeutic approaches. Simply put, by intensifying the relationship between Teva’s team, led by Dr. Iris Grossman, and the MIT-trained Immuneering team, we will be closer to helping match the right patient to the right medicine at the right time.”

Read more about: , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems